On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design

#2058

Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.

Aim(s): RECOSY study aims to analyze the incremental cost and use of resources associated with the presence of uncontrolled as compared to controlled CS in NET pts.

Materials and methods: RECOSY is an observational, multicentre, non-interventional, cross-sectional study in clinical practice. Data are retrospectively collected by 36 medical oncologists/endocrinologists from outpatient clinics at public hospitals in Spain. Eligible pts are ≥18 years old with metastatic G1-G2 NETs under somatostatin analog (SSA) therapy for symptomatic control, and distributed in two groups: a) those with at least one uncontrolled CS episode since SSA treatment initiation and b) pts without uncontrolled CS episodes in the last 12 months (NCT03220087).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Custodio A, Carmona-Bayonas A, Villabona C, Perez M, de La Cruz G,

Keywords: neuroendocrine tumors, carcinoid syndrome, use of resources, costs,